Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 6
pages 1274-1276 (juin 2016)
Doi : 10.1016/j.jaad.2015.12.052
Research Letters

The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review
 

Joshua J. Clark, BS, Aaron M. Secrest, MD, PhD, Christopher M. Hull, MD, Mark J. Eliason, MD, Kristin M. Leiferman, MD, Gerald J. Gleich, MD, Douglas L. Powell, MD
 Department of Dermatology, University of Utah, Salt Lake City, Utah 

Correspondence to: Douglas L. Powell, MD, Department of Dermatology, University of Utah, 30 North 1900 East, 4A330, Salt Lake City, UT 84132Department of DermatologyUniversity of Utah30 North 1900 East, 4A330Salt Lake CityUT84132

 Funding sources: None.
 Conflict of interest: None declared.
 An abstract from this research has been accepted as an E-poster for presentation at the 2016 American Academy of Dermatology Annual Meeting.
 This project was deemed exempt by institutional review board of the University of Utah (IRB # 075035).


Top of the page

© 2016  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@